Cited by 888Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.

Diabetic dyslipidaemia: from basic research to clinical practice*

Open access

Taskinen, M.-R.·2003·Diabetologia

DOI 10.1007/s00125-003-1111-y

Open this paper in CoChat — free account Open PDF

Abstract

The recognition that the increase of plasma triglyceride rich lipoproteins (TRLs) is associated with multiple alterations of other lipoproteins species that are potentially atherogenic has expanded the picture of diabetic dyslipidaemia. The discovery of heterogeneity within major lipoprotein classes VLDL, LDL and HDL opened new avenues to reveal the specific pertubations of diabetic dyslipidaemia. The increase of large VLDL 1 particles in Type 2 diabetes initiates a sequence of events that generates atherogenic remnants, small dense LDL and small dense HDL particles. Together these components comprise the atherogenic lipid triad. Notably the malignant nature of diabetic dyslipidaemia is not completely shown by the lipid measures used in clinical practice. The key question is what are the mechanisms behind the increase of VLDL 1 particles in diabetic dyslipidaemia? Despite the advances of recent years, our understanding of VLDL assembly and secretion is still surprisingly incomplete. To date it is still unclear how the liver is able to regulate the amount of triglycerides incorporated into VLDL particles to produce either VLDL 1 or VLDL 2 particles. The current evidence suggests that the machinery driving VLDL assembly in the liver includes (i) low insulin signalling via PI-3 kinase pathway that enhances lipid accumulation into "nascent " VLDL particles (ii) up-regulation of SREBP-1C that stimulates de novo lipogenesis and (iii) excess availability of "polar molecules" in hepatocytes that stabilizes apo B 100. Recent data suggest that all these steps could be fundamentally altered in Type 2 diabetes explaining the overproduction of VLDL apo B as well as the ability of insulin to suppress VLDL 1 apo B production in Type 2 diabetes. Recent discoveries have established the transcription factors including PPARs, SREBP-1 and LXRs as the key regulators of lipid assembly in the liver. These observations suggest these factors as a new target to tailor more efficient drugs to treat diabetic dyslipidaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-003-1111-y

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Self-citation
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014

Show all 183 references

Sorted by citations

Items 201–300 of 885

The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus
Bonilha, I., Hajduch, É., Luchiari, B., Nadruz, W., Goff, W. L., & Sposito, A. C. (2021) · Metabolites · doi:10.3390/metabo11120807 · Cited by 58
Basal and Insulin Mediated VLDL-Triglyceride Kinetics in Type 2 Diabetic Men
Sørensen, L. P., Andersen, I. R., Søndergaard, E., Gormsen, L. C., Schmitz, O., Christiansen, J. S., & Nielsen, S. (2010) · Diabetes · doi:10.2337/db10-0564 · Cited by 51
A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD
Ashworth, W. B., Davies, N. A., & Bogle, I. D. L. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005105 · Cited by 50
Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c
Li, G., Zhou, F. J., Chen, Y., Zhang, W., & Wang, N. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.024 · Cited by 51
Thymoquinone ameliorates diabetic phenotype in Diet-Induced Obesity mice via activation of SIRT-1-dependent pathways
Karandrea, S., Yin, H., Liang, X., Slitt, A. L., & Heart, E. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185374 · Cited by 51
Metformin and pioglitazone: effectively treating insulin resistance
Staels, B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112732 · Cited by 51
Polyunsaturated Fatty Acids Modulate the Effect of TCF7L2 Gene Variants on Postprandial Lipemia
Warodomwichit, D., Arnett, D. K., Kabagambe, E. K., Tsai, M. Y., Hixson, J. E., Straka, R. J., Province, M. A., An, P., Lai, C., Borecki, I. B., et al. (2009) · Journal of Nutrition · doi:10.3945/jn.108.096461 · Cited by 51
Diabetes and dyslipidemia: characterizing lipoprotein metabolism
TOMKIN, G. H., & Owens, D. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s115855 · Cited by 55
Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins
Dallinga‐Thie, G. M., Dullaart, R. P. F., & van Tol, A. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3280e12685 · Cited by 50
Diabetic HDL Is Dysfunctional in Stimulating Endothelial Cell Migration and Proliferation Due to Down Regulation of SR-BI Expression
Pan, B., Ma, Y., Ren, H., He, Y., Wang, Y., Lv, X., Liu, D., Liang, J., Yu, B., Wang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048530 · Cited by 49
Inhibition of hepatic sulfatase-2 In Vivo : A novel strategy to correct diabetic dyslipidemia
Hassing, C., Mooij, H. L., Guo, S., Monia, B. P., Chen, K., Kulik, W., Dallinga‐Thie, G. M., Nieuwdorp, M., Stroes, E. S. G., & Williams, K. J. (2012) · Hepatology · doi:10.1002/hep.25580 · Cited by 56
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations
Fukuda-Tsuru, S., Anabuki, J., Abe, Y., Yoshida, K., & Ishii, S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.024 · Cited by 49
Antigenic role of the adaptive immune response to d -ribose glycated LDL in diabetes, atherosclerosis and diabetes atherosclerotic patients
Akhter, F., Khan, M. S., Alatar, A. A., Faisal, M., & Ahmad, S. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.013 · Cited by 49
Pediatric Metabolic Syndrome: Pathophysiology and Laboratory Assessment.
Higgins, V., & Adeli, K. (2017) · Europe PMC (PubMed Central) · Cited by 49
The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
Chew, N., Chong, B., Ng, C. H., Kong, G., Chin, Y. H., Xiao, W., Lee, C. J. M., Dan, Y. Y., Muthiah, M. D., & Foo, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.971484 · Cited by 49
A new insight into the treatment of diabetes by means of pan PPAR agonists
Chandra, A., Kaur, P., Sahu, S. K., & Mittal, A. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14020 · Cited by 48
Lipid control in patients with diabetes mellitus
Betteridge, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.23 · Cited by 48
Prevalence and pattern of dyslipidemia in Nepalese individuals with type 2 diabetes
Pokharel, D. R., Khadka, D., Sigdel, M., Yadav, N. K., Acharya, S., Kafle, R., Sapkota, R. M., & Sigdel, T. K. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2465-4 · Cited by 47
Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes
Beeler, N., Riederer, B. M., Waeber, G., & Abderrahmani, A. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.006 · Cited by 51
Prevalence of conventional risk factors in Jordanians with coronary heart disease: The Jordan Hyperlipidemia and Related Targets Study (JoHARTS)
Hammoudeh, A. J., Al-Tarawneh, H., El-Harassis, A., HADDAD, J. A., Mahadeen, Z., Badran, N., Izraiq, M., & Al-Mousa, E. N. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.08.005 · Cited by 46
Liver Fat Content in Type 2 Diabetes: Relationship With Hepatic Perfusion and Substrate Metabolism
Rijzewijk, L. J., van der Meer, R. W., Lubberink, M., Lamb, H. J., Romijn, J. A., Roos, A., Twisk, J. W. R., Heine, R. J., Lammertsma, A. A., Smit, J. W. A., et al. (2010) · Diabetes · doi:10.2337/db09-1201 · Cited by 46
Sestrin2 regulates monocyte activation through AMPK‐mTOR nexus under high‐glucose and dyslipidemic conditions
Sundararajan, S., Jayachandran, I., Balasubramanyam, M., Mohan, V., Venkatesan, B. A., & Manickam, N. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28102 · Cited by 46
Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, and Insulin Resistance in the Southeastern United States
Houston, M. C., Hawkins, R. G., Basile, J., Bestermann, W. H., Egan, B. M., Lackland, D., Moore, M. A., Ferrario, C. M., Reed, J. W., Rogers, P., et al. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200506000-00008 · Cited by 46
Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance
Annuzzi, G., Giacco, R., Patti, L., Di Marino, L., De Natale, C., Costabile, G., Marra, M., Santangelo, C., Masella, R., & Rivellese, A. A. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.12.003 · Cited by 45
Type 2 diabetes mellitus‐related genetic polymorphisms in microRNAs and microRNA target sites (MicroRNAs中与2型糖尿病相关的基因多态性及microRNA靶位)
Gong, W., Xiao, D., Ming, G.-F., Yin, J., Zhou, H., & Liu, Z. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12143 · Cited by 45
Evolution of Lipid Profiles after Bariatric Surgery
Garcia-Marirrodriga, I., Amaya-Romero, C., Ruiz-Diaz, G. P., Fernández, S., Ballesta‐López, C., Pou, J. M., Romeo, J. H., Vilhur, G., Badimón, L., & Ybarra, J. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0534-7 · Cited by 45
Effect of prior moderate exercise on postprandial metabolism in men with type 2 diabetes: Heterogeneity of responses
Gill, J. M. R., Al-Mamari, A., Ferrell, W. R., Cleland, S. J., Perry, C. G., Sattar, N. A., Packard, C. J., CASLAKE, M. J., & Petrie, J. R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.10.007 · Cited by 45
Future Challenges for Microsomal Transport Protein Inhibitors
Wierzbicki, A. S., Hardman, T. C., & Prince, W. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109788340703 · Cited by 45
Atherosclerosis, diabetes and lipoproteins
TOMKIN, G. H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.45 · Cited by 45
Fish oil reduces subclinical inflammation, insulin resistance, and atherogenic factors in overweight/obese type 2 diabetes mellitus patients: A pre-post pilot study
de Souza, D. R., Pieri, B. L. D. S., Comin, V. H., Marques, S. D. O., Luciano, T. F., Rodrigues, M. S., & de Souza, C. T. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107553 · Cited by 45
Obesity and Dyslipidemia
Franssen, R., Monajemi, H., Stroes, E. S. G., & Kastelein, J. J. P. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.06.003 · Cited by 45
Combining a dipeptidyl peptidase‐4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β‐cell function in db/db mice
Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., & Odaka, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00145.x · Cited by 44
Increased VLDL-Triglyceride Secretion Precedes Impaired Control of Endogenous Glucose Production in Obese, Normoglycemic Men
Sørensen, L. P., Søndergaard, E., Nellemann, B., Christiansen, J. S., Gormsen, L. C., & Nielsen, S. (2011) · Diabetes · doi:10.2337/db11-0040 · Cited by 44
Consumption of Terpenoids-Rich Padina pavonia Extract Attenuates Hyperglycemia, Insulin Resistance and Oxidative Stress, and Upregulates PPARγ in a Rat Model of Type 2 Diabetes
Germoush, M. O., Elgebaly, H. A., Hassan, S. M., Kamel, E. M., Bin-Jumah, M. N., & Mahmoud, A. M. (2019) · Antioxidants · doi:10.3390/antiox9010022 · Cited by 46
Effect of eugenol treatment in hyperglycemic murine models: A meta-analysis
Carvalho, R. P. R., Lima, G. D. D. A., & Machado‐Neves, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105315 · Cited by 52
Beneficial Effects of Swertiamarin on Dyslipidaemia in Streptozotocin‐induced Type 2 Diabetic Rats
Vaidya, H. B., Prajapati, A., Rajani, M., Sudarsanam, V., Padh, H., & Goyal, R. K. (2012) · Phytotherapy Research · doi:10.1002/ptr.3708 · Cited by 44
Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2004) · Clinical Science · doi:10.1042/cs20040109 · Cited by 44
The physiology of MASLD: molecular pathways between liver and adipose tissues
Lee, W., Kipp, Z. A., Bates, E. A., Pauss, S. N., Martinez, G. J., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20257571 · Cited by 52
Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
Penno, G., Solini, A., Zoppini, G., Fondelli, C., Trevisan, R., Vedovato, M., Gruden, G., Lamacchia, O., Pontiroli, A. E., Arosio, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125512 · Cited by 43
Association of lipoprotein lipase (LPL) single nucleotide polymorphisms with type 2 diabetes mellitus
Cho, Y. S., Go, M. J., Han, H. R., Cha, S.-H., Kim, H.-T., Min, H., Shin, H. D., Park, C., Han, B., Cho, N. H., et al. (2008) · Experimental & Molecular Medicine · doi:10.3858/emm.2008.40.5.523 · Cited by 43
Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis
Younis, N., Williams, S. D., Ammori, B. J., & Soran, H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003792538 · Cited by 43
Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus—Brief Report
Apro, J., Tietge, U. J. F., Dikkers, A., Parini, P., Angelin, B., & Rudling, M. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307385 · Cited by 44
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Erdmann, E., Dormandy, J., Wilcox, R., Massi‐Benedetti, M., & Charbonnel, B. H. (2007) · PubMed Central · Cited by 43
Tumor necrosis factor α is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy
Haugaard, S. B., Andersen, O., Pedersen, S. B., Dela, F., Fenger, M., Richelsen, B., Madsbad, S., & Iversen, J. (2006) · Metabolism · doi:10.1016/j.metabol.2005.08.018 · Cited by 43
Correction: Pre-Conception Dyslipidemia Is Associated with Development of Preeclampsia and Gestational Diabetes Mellitus
Baumfeld, Y., Novack, L., Wiznitzer, A., Sheiner, E., Henkin, Y., Sherf, M., & Novack, V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142462 · Cited by 43
Effects of hyperinsulinemia on lipoprotein lipase, angiopoietin-like protein 4, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 in subjects with and without type 2 diabetes mellitus
Ruge, T., Sukonina, V., Kroupa, O., Makoveichuk, E., Lundgren, M., Svensson, M. K. E., Olivecrona, G., & Eriksson, J. W. (2011) · Metabolism · doi:10.1016/j.metabol.2011.09.014 · Cited by 42
Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis
Drexel, H., Aczél, S., Marte, T., Vonbank, A., & Saely, C. H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.026 · Cited by 42
Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register
Eriksson, M., Zethelius, B., Eeg‐Olofsson, K., Nilsson, P. M., Guðbjörnsdóttir, S., Cederholm, J., & Eliasson, B. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32833ba61e · Cited by 42
ApoB48 as an Efficient Regulator of Intestinal Lipid Transport
Lo, C. C., & Coschigano, K. T. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00796 · Cited by 42
Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients
Lafontan, M., Piazza, P. V., & Girard, J. R. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.02.001 · Cited by 43
Circulating Immune Complexes among Diabetic Children
Nicoloff, G., Blazhev, A. B., Petrova, C., & Christova, P. (2004) · Journal of Immunology Research · doi:10.1080/10446670410001670517 · Cited by 41
Restenosis after carotid endarterectomy: significance of newly acquired risk factors
Fluri, F., Hatz, F., Voss, B., Lyrer, P. A., & Engelter, S. T. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02858.x · Cited by 41
Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus
Salvadó, L., Serrano, L., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.658370 · Cited by 42
Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus.
Tangvarasittichai, S., Poonsub, P., & Tangvarasittichai, O. (2010) · PubMed · Cited by 40
Metabolic syndrome and type 2 diabetes: lipid and physiological consequences
Chapman, M. J. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.050 · Cited by 40
Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice
Tanaka, H., Nagashima, T., Shimaya, A., Urano, Y., Shimokawa, T., & Shibasaki, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.07.018 · Cited by 38
STRUCTURAL ELUCIDATION OF HUMAN OXIDATIVE METABOLITES OF MURAGLITAZAR: USE OF MICROBIAL BIOREACTORS IN THE BIOSYNTHESIS OF METABOLITE STANDARDS
Zhang, D., Zhang, H., Aranı́bar, N., Hanson, R. L., Huang, Y., Cheng, P. T. W., Wu, S. C., Bonacorsi, S. J., Zhu, M., Swaminathan, A., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007153 · Cited by 39
After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
Colhoun, H. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67668-4 · Cited by 39
Effects of Selective and Non-Selective Glucocorticoid Receptor II Antagonists on Rapid-Onset Diabetes in Young Rats
Beaudry, J. L., Dunford, E. C., Teich, T., Zaharieva, D. P., Hunt, H., Belanoff, J. K., & Riddell, M. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091248 · Cited by 37
Changes on serum and hepatic lipidome after a chronic cadmium exposure in Wistar rats
Sarmiento-Ortega, V. E., Treviño, S., Flores-Hernández, J. Á., Aguilar‐Alonso, P., Moroni-González, D., Aburto-Luna, V., Díaz, A., & Brambila, E. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.10.003 · Cited by 37
HDL Subspecies in Young Adult Twins: Heritability and Impact of Overweight
Pietiläinen, K. H., Söderlund, S., Rissanen, A., Nakanishi, S., Jauhiainen, M., Taskinen, M., & Kaprio, J. A. (2009) · Obesity · doi:10.1038/oby.2008.675 · Cited by 38
Self-citation
The impact of thiamine supplementation on blood pressure, serum lipids and C-reactive protein in individuals with hyperglycemia: a randomised, double-blind cross-over trial
Alaei-Shahmiri, F., Soares, M. J., Zhao, Y., & Sherriff, J. L. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.04.014 · Cited by 38
Synthesis of Fructose Biosensors and Progressing Their Efficiency Using Californium Colloidal Nanoparticles for Detecting Fructose and Triglycerides
Heidari, A. (2020) · Advanced Science Engineering and Medicine · doi:10.1166/asem.2020.2635 · Cited by 36
Plasma proprotein convertase subtilisin–kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients
Kappelle, P. J. W. H., Lambert, G. C., & Dullaart, R. P. F. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.028 · Cited by 37
Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very‐low‐density lipoprotein particle concentrations in statin‐treated type 2 diabetic patients
Chan, D. C., Hamilton, S. J., Rye, K.-A., Chew, G., Jenkins, A. J., Lambert, G. C., & Watts, G. F. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01229.x · Cited by 39
VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly
Croyal, M., Blanchard, V., Ouguerram, K., Chétiveaux, M., Cabioch, L., Moyon, T., Billon‐Crossouard, S., Aguesse, A., Bernardeau, K., May, C. L., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313877 · Cited by 37
Effects of chromium supplementation on lipid profile in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of randomized controlled trials
Asbaghi, O., Naeini, F., Ashtary‐Larky, D., Moradi, S., Zakeri, N., Eslampour, E., Kelishadi, M. R., & Naeini, A. A. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126741 · Cited by 36
Analysis of polyphenols in Aegle marmelos leaf and ameliorative efficacy against diabetic mice through restoration of antioxidant and anti‐inflammatory status
Ibrahim, M., Parveen, B., Zahiruddin, S., Gautam, G., Parveen, R., Khan, M. A., Gupta, A. K., & Ahmad, S. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13852 · Cited by 36
Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion‐exchange resins, omega‐3 fatty acids: which drugs for which patients?
Drexel, H. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00745.x · Cited by 33
Role for Combination Therapy in Diabetic Dyslipidemia
Warraich, H. J., Wong, N. D., & Rana, J. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0589-5 · Cited by 36
Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
Gastaldelli, A., Casolaro, A., Ciociaro, D., Frascerra, S., Nannipieri, M., Buzzigoli, E., & Ferrannini, E. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90960.2008 · Cited by 37
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
Lund, S. S., Tarnow, L., Frandsen, M., Smidt, U., Pedersen, O. B., Parving, H., & Vaag, A. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0500 · Cited by 34
Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets
Favre, D., Niederhäuser, G., Fahmi, D., Plaisance, V., Brajkovic, S., Beeler, N., Allagnat, F., Haefliger, J., Regazzi, R., Waeber, G., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2165-x · Cited by 38
Blighia sapida leaves halt elevated blood glucose, dyslipidemia and oxidative stress in alloxan-induced diabetic rats
Oloyede, O. B., Ajiboye, T. O., Abdus-salam, A. F., & Adeleye, A. O. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.08.022 · Cited by 35
Lipoprotein subfractions and dietary intake of n-3 fatty acid: the Genetics of Coronary Artery Disease in Alaska Natives study
Annuzzi, G., Rivellese, A. A., Wang, H., Patti, L., Vaccaro, O., Riccardi, G., Ebbesson, S. O. E., Comuzzie, A. G., Umans, J. G., & Howard, B. V. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.023887 · Cited by 35
Hypertriglyceridemia, an important and independent risk factor for acute pancreatitis in patients with type 2 diabetes mellitus
Albai, O., Roman, D., & Frandeș, M. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s134560 · Cited by 35
Prevalence and pattern of dyslipidemia in patients with type 2 diabetes mellitus in Zaria, Northwestern Nigeria
Bello-Ovosi, B. O., Ovosi, J. O., Ogunsina, M. A., Asuke, S., & Ms, I. (2019) · Pan African Medical Journal · doi:10.11604/pamj.2019.34.123.18717 · Cited by 44
Sesamol alleviates diet-induced cardiometabolic syndrome in rats via up-regulating PPARγ, PPARα and e-NOS
Sharma, A. K., Bharti, S., Bhatia, J., Nepal, S., Malik, S., Ray, R., Kumari, S., & Arya, D. S. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.09.011 · Cited by 36
GLUCURONIDATION AS A MAJOR METABOLIC CLEARANCE PATHWAY OF 14C-LABELED MURAGLITAZAR IN HUMANS: METABOLIC PROFILES IN SUBJECTS WITH OR WITHOUT BILE COLLECTION
Wang, L., Zhang, D., Swaminathan, A., Xue, Y., Cheng, P. T. W., Wu, S. C., Mosqueda‐Garcia, R., Aurang, C., Everett, D. W., & Humphreys, W. G. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007617 · Cited by 35
Parallel increase of plasma apoproteins C‐II and C‐III in Type 2 diabetic patients
Béliard, S., Nogueira, J. P., Maraninchi, M., Lairon, D., Nicolay, A., Giral, P., Portugal, H., Vialettes, B., & Valéro, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02757.x · Cited by 34
Relationships between hepatic stearoyl-CoA desaturase-1 activity and mRNA expression with liver fat content in humans
Peter, A., Čegan, A., Wagner, S., Elcnerova, M., Königsrainer, A., Königsrainer, I., Häring, H., Schleicher, E. D., & Stefan, N. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00306.2010 · Cited by 34
Good Cholesterol Gone Bad? HDL and COVID-19
Kluck, G. E. G., Yoo, J., Sakarya, E. H., & Trigatti, B. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910182 · Cited by 37
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
Josloff, K., Beiriger, J., Khan, A., Gawel, R. J., Kirby, R. S., Kendrick, A. D., Rao, A. K., Wang, R. X., Schafer, M., Pearce, M. E., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120419 · Cited by 35
Kinetic studies to investigate lipoprotein metabolism
Borén, J., Taskinen, M., & Adiels, M. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02497.x · Cited by 37
Self-citation
Insulin Resistance: Pathophysiology and Rationale for Treatment
Muntoni, S., & Muntoni, S. (2011) · Annals of Nutrition and Metabolism · doi:10.1159/000323395 · Cited by 34
Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes
Vergès, B. L., Florentin, E., Baillot-Rudoni, S., Petit, J., Brindisi, M., de Barros, J.-P. P., Lagrost, L., Gambert, P., & Duvillard, L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p800040-jlr200 · Cited by 35
Supra-additive effect of chronic inflammation and atherogenic dyslipidemia on developing type 2 diabetes among young adults: a prospective cohort study
Lan, Y., Wu, D., Cai, Z., Xu, Y., Ding, X., Wu, W., Lan, S., Chen, L., Guo, Z., Balmer, L. A., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01878-5 · Cited by 34
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.04.005 · Cited by 33
Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis
Marku, A., Dalt, L. D., Galli, A., Dule, N., Corsetto, P. A., Rizzo, A. M., Moregola, A., Uboldi, P., Bonacina, F., Marciani, P., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155291 · Cited by 36
Clinical significance of the physicochemical properties of LDL in type 2 diabetes
Scheffer, P. G., Teerlink, T., & Heine, R. J. (2005) · Diabetologia · doi:10.1007/s00125-005-1736-0 · Cited by 34
Positive association between plasma IGF1 and high-density lipoprotein cholesterol levels in adult nondiabetic subjects
Succurro, E., Arturi, F., Grembiale, A., Iorio, F., Laino, I., Andreozzi, F., Sciacqua, A., Hribal, M. L., Perticone, F., & Sesti, G. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0113 · Cited by 32
Environmental and Genetic Determinants of Fatty Liver in Humans
Kantartzis, K., Schick, F., Häring, H., & Stefan, N. (2010) · Digestive Diseases · doi:10.1159/000282082 · Cited by 32
A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies
Simons, N., Dekker, J. M., van Greevenbroek, M. M. J., Nijpels, G., Hart, L. M. ‘., Kallen, C., Schalkwijk, C. G., Schaper, N. C., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2016) · Diabetes Care · doi:10.2337/dc16-0153 · Cited by 30
Endotoxemia is associated with an adverse metabolic profile
Määttä, A.-M., Salminen, A., Pietiäinen, M., Leskelä, J., Palviainen, T., Sattler, W., Sinisalo, J. P., Salomaa, V. V., Kaprio, J. A., & Pussinen, P. J. (2020) · Innate Immunity · doi:10.1177/1753425920971702 · Cited by 32
Beneficial effects of walnut (Juglans regia L.) oil-derived polyunsaturated fatty acid prevents a prooxidant status and hyperlipidemia in pregnant rats with diabetes
Sun, B., Yan, H., Li, C., Yin, L., Li, F. R., Zhou, L., & Han, X. (2020) · Nutrition & Metabolism · doi:10.1186/s12986-020-00514-3 · Cited by 32
Fatty Acids Cause Alterations of Human Arterial Smooth Muscle Cell Proteoglycans That Increase the Affinity for Low-Density Lipoprotein
Rodrı́guez-Lee, M., Östergren‐Lundén, G., Wallin, B., Moses, J., Bondjers, G., & Camejo, G. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191659.94059.62 · Cited by 33
Microsomal triglyceride transfer protein polymorphisms and lipoprotein levels in type 2 diabetes
Phillips, C. M., Mullan, K., Owens, D., & TOMKIN, G. H. (2004) · QJM · doi:10.1093/qjmed/hch040 · Cited by 32
Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus
Kalmár, T., Seres, I., Balogh, Z., Káplár, M., Winkler, G., & Paragh, G. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70233-1 · Cited by 32
Diabetes Mellitus-Associated Atherosclerosis
Calkin, A. C., & Allen, T. J. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606010-00003 · Cited by 31
PPAR Agonists and Cardiovascular Disease in Diabetes
Calkin, A. C., & Thomas, M. C. (2008) · PPAR Research · doi:10.1155/2008/245410 · Cited by 30

Authors: Taskinen, M.-R.
Affiliations: University of Helsinki (FI)
Corresponding author: Taskinen, M.-R.
ORCID: Taskinen, M.-R.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2003-06-01
Volume: 46
Issue: 6
Pages: 733-749
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-003-1111-y
OpenAlex: W2020659754
Cited by: 888
References: 183
Citations by year: 2026: 27 · 2025: 37 · 2024: 32 · 2023: 36 · 2022: 48 · 2021: 41 · 2020: 39 · 2019: 27 · 2018: 32 · 2017: 28 · 2016: 29 · 2015: 47 · 2014: 41 · 2013: 46 · 2012: 42
FWCI: 6.10
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Funders: Helsingin ja Uudenmaan Sairaanhoitopiiri
Academy of Finland
Diabetesliitto
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: diabetic dyslipidemia, type 2 diabetes, small dense LDL, triglyceride-rich lipoproteins, VLDL assembly, hepatic lipid metabolism, insulin signaling, PI3-kinase, SREBP-1c, de novo lipogenesis, apolipoprotein B-100, peroxisome proliferator-activated receptors, SREBP1, liver X receptor
MeSH terms: Diabetes Mellitus, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Lipoproteins, Lipoproteins, VLDL, Diabetes Complications, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diabetic dyslipidaemia: from basic research to clinical practice*

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks